Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderna Bivalent vs Novavax as 4th Dose COVID-19 Vaccine in Healthy Adults
NCT05658523Phase 3Active, not recruiting
- Sponsor
- Murdoch Children's Research Institute
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elasomeran + imelasomeran and NVX-CoV2373 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Murdoch Children's Research Institute. Primary endpoints: SARS-CoV-2 Specific Immunoglobulin (Ig)G Antibodies at 28 days and Total Incidence of Solicited Reactions (Systemic and Local) at 7 days. Started Feb 2023; status: active, not recruiting.
02
Drugs
elasomeran + imelasomeranNVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05658523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658523.